Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals director receives equity grant. Director Ryan Barbara was granted 3,722 shares of Indivior Pharmaceuticals, Inc. common stock on January 26, 2026 as a stock-based award at a price of $0 per share. After this grant, Barbara beneficially owns 5,685 common shares in total.
The award is in the form of restricted stock units (RSUs), each representing the right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, contingent on Barbara’s continued service to the company through that vesting date.
Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units. On 01/26/2026 he was awarded 3,722 RSUs, recorded at a price of $0 per unit, increasing his beneficial ownership to 20,645 shares of common stock held directly.
The RSUs each represent a right to receive one share of Indivior common stock. They vest on the day immediately before the first annual meeting of stockholders following the grant date, as long as he continues to serve the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Mark Stejbach reported a grant of 3,722 shares of common stock in the form of Restricted Stock Units on January 26, 2026 at a price of $0 per share. Following this award, he beneficially owns 20,569 common shares in total.
Each RSU represents the right to receive one share of common stock and will vest on the day immediately before the first annual stockholders’ meeting after the grant date, as long as Stejbach continues serving the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Juliet Thompson reported a grant of 3,722 restricted stock units of common stock on January 26, 2026 at a price of $0 per share. After this award, she beneficially owns 7,572 shares directly, with an additional 5,775 shares held indirectly by her spouse. The RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, subject to her continued service.
Indivior Pharmaceuticals director Keith Humphreys received an equity grant of 3,722 shares of common stock on January 26, 2026, reported as an acquisition at a price of $0 per share. Following this grant, he beneficially owns 9,524 shares directly.
The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to one share of common stock. The RSUs vest on the day immediately preceding the first annual stockholders’ meeting after the grant date, conditioned on his continued service as of the vesting date.
Indivior Pharmaceuticals, Inc., a new Delaware corporation, has completed a U.S. domestication in which it became the ultimate parent of Indivior PLC and its subsidiaries through a court-approved scheme of arrangement. Each Indivior PLC ordinary share was cancelled and replaced on a one-for-one basis with Indivior Pharmaceuticals common stock, par value $0.001 per share. Indivior PLC ordinary shares ceased trading on Nasdaq, and Indivior Pharmaceuticals common stock now trades on the Nasdaq Global Select Market under the same symbol, INDV, with CUSIP 45579U109.
The company amended an existing note purchase agreement so financial reporting is now provided by Indivior Pharmaceuticals, and authorized indemnification agreements for its directors and executive officers to the fullest extent permitted under Delaware law. The same directors and executive officers continue in their roles, and existing equity plans were assumed and amended so awards will settle in Indivior Pharmaceuticals common stock.
Indivior Pharmaceuticals also adopted a new 2026 Omnibus Equity Incentive Plan reserving up to 17,500,000 shares, subject to recycling of forfeited awards, as well as a detailed non‑employee director compensation policy that combines cash retainers with annual and one‑time restricted stock unit awards.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 17,806,183 shares of INDIVIOR PLC common stock, representing 14.3% of the outstanding class as of the event date. BlackRock reports sole power to vote 17,585,684 shares and sole power to dispose of 17,806,183 shares, with no shared voting or dispositive power.
The filing is made on a passive basis under Schedule 13G, with BlackRock certifying that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior. The filing notes that one investor, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Indivior’s outstanding common stock.
Indivior PLC filed a current report stating that on January 8, 2026 it issued a press release providing its financial guidance for 2026 and updated its corporate presentation. These materials are being made available to investors as supplemental information.
The 2026 financial guidance press release is included as Exhibit 99.1 and the updated corporate presentation is included as Exhibit 99.2 to the report, giving the market more detail on Indivior’s expected performance and strategic messaging for the year.
Indivior PLC director Ryan Barbara reported acquiring 775 Ordinary Shares on January 5, 2026 at a price of $35.3926 per share. These shares were received through participation in a Non-Executive Director Purchase Plan, under which a portion of director fees is taken in stock instead of cash. Following this transaction, Barbara beneficially owned 1,963 Ordinary Shares directly. This reflects a routine equity-based compensation election rather than an open-market investment decision.